Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.37 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4596390 | 0.91 | GLO1 (0.39) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| SCHEMBL9313077 | 0.88 | ALDH1A1 (0.50) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| SCHEMBL322669 | 0.85 | — | — | |
| SCHEMBL9313073 | 0.81 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| Acetic Acid SCHEMBL29011975 | 0.79 | ALDH1A1 (0.53) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| Acetic Acid SCHEMBL28767597 | 0.79 | ALDH1A1 (0.53) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| SCHEMBL14409231 | 0.79 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| SCHEMBL9311639 | 0.79 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| SCHEMBL2625617 | 0.79 | TSHR (0.52) | ALDH1A1LMNAHSD17B10TSHRCHRM5 | |
| SCHEMBL2175591 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239154-A1 | PYRUVATE AND RELATED ALPHA-KETO CARBOXYLATES AS NOVEL ADJUVANTS IN THE TREATMENT OF POST TOOTH WHITENING SENSITIVITY AND THE TISSUE PROTECTIVE EFFECT OF PYRUVATE ON THE ORAL SOFT TISSUE | RUSZNAK ZOLTAN (US) | 2017-08-24 | — | — | US | claimed |
| US-8815946-B2 | Inhibition of proliferation and fibrotic response of activated corneal stromal cells | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2014-08-26 | — | — | US | claimed |
| US-20090239947-A1 | Inhibition of proliferation and fibrotic response of activated corneal stromal cells | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2009-09-24 | — | — | US | claimed |
| EP-1937316-A2 | RADIOPROTECTIVE AGENTS | University of Pittsburgh of the Commonwealth System of Higher Education (US) | 2008-07-02 | — | — | EP | claimed |
| EP-1635806-B1 | METHOD FOR TREATING ALCOHOLIC HEPATITIS | UNIV PITTSBURGH (US) | 2008-05-28 | — | — | EP | claimed |
| WO-2007014237-A2 | RADIOPROTECTIVE AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-02-01 | — | — | WO | claimed |
| US-20060223887-A1 | Method for treating acute pancreatitis | UNIVERSITY OF PITTSBURGH- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2006-10-05 | — | — | US | claimed |
| EP-1233767-B1 | PYRUVATE ESTER COMPOSITION AND METHOD OF USE FOR RESUSCITATION AFTER EVENTS OF ISCHEMIA AND REPERFUSION | XANTHUS LIFE SCIENCES INC (CA) | 2006-04-12 | — | — | EP | claimed |
| EP-1635806-A2 | METHOD FOR TREATING ALCOHOLIC HEPATITIS | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-03-22 | — | — | EP | claimed |
| EP-1494659-B1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT | CRITICAL THERAPEUTICS INC (US) | 2005-10-12 | — | — | EP | claimed |
| EP-1496883-A1 | METHOD FOR TREATING ILEUS WITH AN ALPHA-KETOALKANOIC ACID, ESTER OR AMIDE | Critical Therapeutics, Inc. (US) | 2005-01-19 | — | — | EP | claimed |
| WO-2005002563-A2 | METHOD FOR TREATING ALCOHOLIC HEPATITIS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCTION (US) | 2005-01-13 | — | — | WO | claimed |
| EP-1494659-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT | Critical Therapeutics, Inc. (US) | 2005-01-12 | — | — | EP | claimed |
| US-20030232884-A1 | New pharmaceutical formulation | CRITICAL THERAPEUTICS, INC. | 2003-12-18 | — | — | US | claimed |
| US-20030216470-A1 | Method for treating ileus | CRITICAL THERAPEUTICS, INC. | 2003-11-20 | — | — | US | claimed |
| WO-2003088956-A1 | METHOD FOR TREATING ILEUS WITH AN ALPHA -KETOALKANOIC ACID OR - ESTER OR - AMIDE | CRITICAL THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| WO-2003088955-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMINE AND LACTIC ACID OR A LACTIC ACID SALT | CRITICAL THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-20030073743-A1 | Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion | XANTHUS LIFE SCIENCES, INC. (CA) | 2003-04-17 | — | — | US | claimed |
| EP-1233767-A1 | PYRUVATE ESTER COMPOSITION AND METHOD OF USE FOR RESUSCITATION AFTER EVENTS OF ISCHEMIA AND REPERFUSION | Xanthus Life Sciences, Inc. (CA) | 2002-08-28 | — | — | EP | claimed |
| WO-2001024793-A1 | PYRUVATE ESTER COMPOSITION AND METHOD OF USE FOR RESUSCITATION AFTER EVENTS OF ISCHEMIA AND REPERFUSION | XANTHUS LIFE SCIENCES, INC. (CA) | 2001-04-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223887-A1 | Method for treating acute pancreatitis | PNLIP, LIPA, AMY2A | ALDH1A1 1468/4885LMNA 3716/4885HSD17B10 227/4885 |
| US-20030232884-A1 | New pharmaceutical formulation | LIPA, CEL, LDHA | ALDH1A1 227/4885LMNA 1853/4885HSD17B10 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.